Ask AI
ProCE Banner Activity

VIKTORIA-1: Gedatolisib + Fulvestrant ± Palbociclib vs Fulvestrant in HR+/HER2- Advanced Breast Cancer With PIK3CA Wild-Type Status

Conference Coverage
Slideset

Interim analysis of the phase III VIKTORIA-1 trial showed statistically significant and clinically meaningful improvement in PFS with gedatolisib combined with fulvestrant with or without palbociclib vs fulvestrant in patients with HR+/HER2- PIK3CA wild-type advanced breast cancer that had disease progression following previous NSAI plus CDK4/6 inhibitor therapy. 

Released: October 31, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., Gilead Sciences, Inc., Incyte, and Lilly.

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Incyte

Lilly